Avingtrans delivered improved margins and earnings in the first half, supported by stronger aftermarket activity and disciplined debt control. While revenue was flat year-on-year, management expects the usual second-half weighting to return, aided by nuclear contracts and rising data centre cooling demand. With Adaptix now FDA approved and US distributors appointed, medical imaging enters a critical commercial phase alongside growing exposure to AI-driven nuclear build-out...